Aortic aneurysms are life-threatening conditions with effective treatments mainly limited to emergency surgery or trans-arterial endovascular stent grafts, thus calling for the identification of specific molecular targets. Genetic studies have highlighted controversial roles of transforming growth factor b (TGF-b) signaling in aneurysm development. Here, we report on aneurysms developing in adult mice after smooth muscle cell (SMC)-specific inactivation of Smad4, an intracellular transducer of TGF-b. The results revealed that Smad4 inhibition activated interleukin-1b (IL-1b) in SMCs. This danger signal later recruited innate immunity in the adventitia through chemokine (C-C motif) ligand 2 (CCL2) and modified the mechanical properties of the aortic wall, thus favoring vessel dilation. SMC-specific Smad4 deletion in Il1r1-or Ccr2-null mice resulted in milder aortic pathology. A chronic treatment with anti-IL-1b antibody effectively hampered aneurysm development. These findings identify a mechanistic target for controlling the progression of aneurysms with compromised TGF-b signaling, such as those driven by SMAD4 mutations.
In Brief TGF-b signaling has an unquestionable but still controversial role in the pathogenesis of aortic aneurysm. Da Ros et al. demonstrate that disruption of TGF-b signaling in SMCs activates an autocrine IL-1b pathway that acts as a danger signal to recruit innate immune cells in the adventitia through CCL2.
INTRODUCTION
Defined as a progressive dilation of the vessel, with tube-shaped (fusiform) or round (saccular) enlargements, aortic aneurysms are a significant cause of mortality and morbidity in the western world; they have no clinical treatment other than high-risk surgery or trans-arterial endovascular therapies with stent grafts when the conditions of patients are favorable to this option (Davis et al., 2014; Milewicz et al., 2008) . However, the indication for intervention is generally reserved for large aneurysms, and no effective therapy contrasts the evolution of aneurysms at initial stages. This shortage of clinical approaches is mainly a result of insufficient insights into the early pathogenetic mechanisms of aneurysm formation. Among the proposed signals involved, components of the transforming growth factor b (TGF-b) pathway have an unquestionable but still controversial role in the pathogenesis of aortic aneurysms (Gillis et al., 2013; Lindsay and Dietz, 2011) .
When mutated, genes encoding components of the TGF-b pathway can cause the formation of aortic aneurysms, leading to, for instance, Loeys-Dietz syndrome (LDS) (Gillis et al., 2013) . The observation that aortic tissue from LDS patients has defective TGF-b signaling components but paradoxically enhanced TGF-b activity, as shown by increased phosphorylation of its downstream intracellular signaling SMAD2, led to the proposal that TGF-b hyperactivity accounts for the aortic pathology (Gillis et al., 2013; Holm et al., 2011) . However, it should not be neglected that other studies have suggested a protective role of TGF-b activity in the process of aneurysm development (Bertoli-Avella et al., 2015; Lindsay et al., 2012; van de Laar et al., 2011; Yang et al., 2016) .
The TGF-b pathway is mediated through the phosphorylation of and interaction between Smad2 and Smad3 and the common interactor Smad4, which all form a complex that regulates gene transcription in the nucleus (Shi and Massagué , 2003) . Human syndromes resulting from SMAD4 mutations also include highfrequency aortic aneurysms (Andrabi et al., 2011; Heald et al., 2015; Teekakirikul et al., 2013) . Given that Smad4 is an obligatory component of the canonical TGF-b pathway, targeting its encoding gene has been exploited as a strategy for unraveling the role of TGF-b signaling in aortic pathology. Because wholegenome Smad4 ablation is embryonically lethal in mice, Zhang et al. recently demonstrated that the conditional deletion of Smad4 in Acta2-expressing smooth muscle cells (SMCs) induces aortic aneurysms (Zhang et al., 2016) . Although it informs the causal link between Smad4 loss of function and aneurysm formation, the pathology developed in these mice is very severe and does not allow thorough investigation of the mechanisms.
To this aim, we induced a targeted deletion of Smad4 in adult mice by using a tamoxifen-inducible Cre recombinase under the control of the SMC promoter. This study demonstrates a key mechanistic role of structural alterations and immune and inflammatory processes driven by interleukin-1b (IL-1b) produced by SMCs in aortic aneurysms deriving from disrupted canonical TGF-b signaling in SMCs. The activation of IL-1b as a danger signal of SMCs subsequently recruits innate immune cells by activating monocyte chemoattractant protein 1 (MCP-1), also referred to as chemokine (C-C motif) ligand 2 (CCL2), and its cognate receptor C-C chemokine receptor type 2 (CCR2). More important, administration of a neutralizing anti-IL-1b antibody protects against the evolution of aortic pathology, opening the way to translational therapeutic approaches in aneurysms with compromised canonical TGF-b signaling, such as those driven by SMAD4 mutations.
RESULTS

Deletion of SMC-Specific Smad4 in Adult Mice Causes Aneurysmal Formation in the Aorta
To dissect the causal link between defective TGF-b signaling in the vasculature and aneurysm formation, we generated a murine model with SMC-specific deletion of Smad4, the common intracellular interactor of canonical TGF-b signaling. To avoid the confounding effects of inactivation of TGF-b signaling during development, we used an inducible Cre-loxP system driven by a smooth muscle myosin heavy chain promoter, Myh11, to delete Smad4 selectively in SMCs of adult mice. We treated Smad4 f/f ;Myh11-creERT2 mice (abbreviated as Smad4-SMC in the figures) with tamoxifen to allow Cre-mediated recombination of Smad4 in SMCs (referred to as Smad4-SMC iko mice in the figures), whereas control groups received only vehicle (referred to as Smad4-SMC WT mice in the figures). Analysis of Smad4 in aortas dissected 1 week later showed lower amounts in tamoxifen-treated mice than in animals that had received vehicle alone ( Figure S1A ). Additional analyses showed that less Smad4 was specifically detectable in tamoxifen-treated mice carrying the Smad4 mutation than in mice without the mutation (Smad4 +/+ ;Myh11-creERT2) ( Figure S1A ). Immunofluorescence analysis further demonstrated that the deficiency of Smad4 was confined to the media layer and did not affect the endothelium (Figures S1B and S1C) .
Before proceeding with the characterization of aortic pathology, we assessed the general cardiovascular function of tamoxifen-treated Smad4 f/f ;Myh11-creERT2 mice and vehicle-treated
;Myh11-creERT2 mice at day 0 and the following time points. Initial (basal) and final (16 weeks) analyses, shown in Table S1 , indicated that SMC-specific Smad4 deletion affected neither blood pressure nor cardiac structure and function. Serial ultrasonographical analyses of the whole aorta, performed every 4 weeks for up to 16 weeks starting at day 0 after tamoxifen or vehicle administration, revealed that the aortas of Smad4 f/f ; Myh11-creERT2 mice treated with tamoxifen progressively enlarged, whereas none of the vehicle-treated control mice showed any significant variation from their basal condition (Figures 1A-1C) .
At gross autoptic examination, all aortas of Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen displayed one or more evident pathologies, mainly manifested as enlargements and dilations, whereas aortas from Smad4 f/f ;Myh11-creERT2 mice treated with vehicle appeared normal ( Figure 1D ). Regarding the prevalence of aortic pathologies, we found 100% penetrance in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen, and the timing of their appearance varied by aortic region ( Figure 1E schematically depicts the locations of the aneurysms). The ascending portion of the aorta showed a mildly enlarged diameter at 4 weeks and culminated in the formation of aneurysms at 8 weeks ( Figures 1A-1C) . Conversely, ultrasonographic monitoring of the abdominal aorta revealed that aneurysms formed later at 12 weeks ( Figures 1F-1H ). Because of the earliest aneurysmal appearance in the ascending aorta, we focused our mechanistic evaluations on this location throughout the study.
As shown in the Kaplan-Meier plot, the survival of Smad4 f/f ; Myh11-creERT2 mice treated with tamoxifen was severely reduced after Smad4 deletion, whereas none of the control Smad4 f/f ;Myh11-creERT2 mice treated with vehicle died during the observation time ( Figure 1I ). In particular, the mortality of Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen was nearly 30% during the time frame of ultrasonographic analysis (i.e., within 16 weeks after Smad4 deletion), when mice died of aneurysm rupture, as indicated by the presence of hemothorax at necropsy. Structural disarrangement of the ascending aorta media in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen was clearly appreciated as discrete breaks of elastic lamellae 8 weeks after tamoxifen-induced Smad4 deletion (Figures 2A-2C ). Unlike aortopathies, which are characterized by degenerative changes and identified as cystic medial necrosis (Guo et al., 2001) , the islands of damage detected in the aortas of Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen were not deprived of cells but rather contained groups of cells with spindle-shaped nuclei ( Figure S1D ). In addition, the sites of break did not show amorphous matrix deposition, as implied by the reduction of (E) Schematic representation of the entire aorta shows the different segments analyzed and indicates the locations where aneurysms developed (black arrows) in Smad4-SMC iko mice.
(F and G) Progression of abdominal aorta pathology in Smad4-SMC iko mice (G) and control mice (F). Scale bars, 1 mm.
(H) Quantitative analysis of abdominal aortic diameters of n = 9 mice per group. Two-way ANOVA for repeated measures: df = 4; F (interaction) = 16.34.
(I) Kaplan-Meier plot for Smad4-SMC iko (n = 17) and Smad4-SMC WT (n = 15) mice shows significantly increased mortality after Smad4 deletion. Log rank test: df = 1, c 2 = 34.62, p < 0.0001. *p < 0.05, **p < 0.01, ***p < 0.001.
Please also see Figures S1A-S1C, S7A, and S7B.
histochemical staining for mucopolysaccarides (Figures S1E and S1F) . Immunostaining for collagen I in lamellae breaks was lower in the media of Smad4
;Myh11-creERT2 mice treated with tamoxifen than in that of control Smad4 f/f ;Myh11-creERT2 mice treated with vehicle ( Figures S1G and S1H ). With time, the severity of damage increased (Figures 2A-2C , 16 weeks), (C) Quantitation of breaks of elastic lamellae in ascending aorta. n = 11 mice per group at 8 weeks and 4 mice per group at 16 weeks. Two-way ANOVA: df = 1; F (interaction) = 10.30; **p < 0.01, ***p < 0.001. (D) Remodeling of the wall structure of ascending aorta. Representative sections of ascending aortas from 11 mice per group at 8 weeks and 4 mice per group at 16 weeks were stained with antibodies to a-SMA and ER-TR7, an antigen expressed by adventitial fibroblasts. Scale bars, 50 mm.
Please also see Figures S1D-S1H.
and zones with staked fragmentations of elastic lamellae became apparent ( Figure 2A , 16 weeks, arrow). In the adventitia of the aortas of Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen, structural remodeling also determined a thickening of this layer (asterisks in Figure 2A ) and, at some sites, penetration of cells into the media. This process could be followed by staining of adventitial fibroblasts and media with antibody to ER-TR7 and a-smooth muscle actin (a-SMA) ( Figure 2D ). In control mice, a thin layer of ER-TR7 + cells marked the adventitia, whereas the media uniformly expressed a-SMA ( Figure 2D ). However, 8 weeks after Smad4 deletion, the ER-TR7 + cells were detected in the thickened adventitia (asterisk in Figure 2D ) and were also found among SMCs (arrowheads in Figure 2D ). When alterations of elastic lamellae were more severe, most cells appeared negative for both a-SMA and ER-TR7 expression (star in Figure 2D , 16 weeks), whereas some staining remained at the border of these sites (thick arrows in Figure 2D , 16 weeks). 8 weeks after Smad4 deletion in SMCs, adventitial inflammation was clearly present in those regions of the media with fragmentation of elastic lamellae. The immune infiltrate ( Figure 3A ) was composed mainly of monocyte and macrophages, as indicated by the abundance of CD11b + ( Figure 3B ) and CD68 + (Figure 3C ) cells and the near absence of lymphocytes (CD3 staining in Figure S1I ). Adventitial gathering of immune cells was always found in locations of the media with discrete stacked breaks of elastic lamellae, indicating a strict association between damage of the media and the presence of inflammatory infiltrate in the adventitia. In accordance, flow-cytometric analysis of cells from aortas isolated 8 weeks after tamoxifen treatment detected a significantly increased number of infiltrating leukocytes gated as CD45 + and marked as CD11b + Ly6C high monocytes and CD11b + Ly6C low macrophages ( Figures 3D-3I ).
Disruption of TGF-b Signaling Induces Early Mechanical
Alterations of the Aorta with No Overt Sign of Inflammation Growth of aortic aneurysms is a process typically accompanied by increased circumferential wall stress (Raaz et al., 2015) . Even though wall stress is usually believed to surge as a consequence of the vessel's expanding geometry, contributing to the eventual rupture of advanced aneurysms, it is also conceivable that enhanced circumferential wall stress occurs because of early biomechanical alterations at pre-aneurysmal stages, thus contributing to the etiology of the disease itself. On this note, aortic aneurysms usually display a mechanical behavior different from that of non-aneurysmal tissue (He and Roach, 1994) , and immune response in tissue remodeling participates in this process (Daugherty and Powell, 2014; Jagadesham et al., 2008) . To find out whether changes in mechanical properties and recruitment of immune response are early events of the pathogenetic cascade triggered by Smad4 inactivation and not a simple consequence of aortic disarrangement accompanying aneurysm formation, we investigated both mechanics and immune response at a time point preceding the signs of aneurysm formation, i.e., 3 weeks after tamoxifen or vehicle administration, when aortic diameters measured by ultrasound imaging were still comparable between the two groups ( Figure S2A ).
To test the intrinsic mechanical properties of the aorta after Smad4 deletion, we excised the ascending portion of the vessel and mounted it on a pressure myograph. We analyzed the structural and functional parameters by subjecting vessels to increasing perfusion pressures. Ascending aorta segments exhibited increased outer ( Figure 4A ) and inner ( Figure S2B ) diameters at increasing perfusion pressure steps. Wall thickness ( Figure S2C ) and the wall-to-lumen ratio ( Figure 4B ) decreased, reaching statistical significance at low intraluminal pressures. Although modifications of the above parameters increased circumferential wall stress ( Figure S2D ), circumferential strain ( Figure S2E ) was comparable between vessels from mutant and control animals. Relevant to this last observation, the stress-strain curves showed significantly more aortic stiffness in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen than in Smad4 f/f ;Myh11-creERT2 mice treated with vehicle (Figure 4C) . Accordingly, the incremental elastic modulus, an intrinsic vessel property independent from the geometry, was increased at high pressures ( Figure 4D) . At the microstructural level, alterations of the vessel wall were detectable as well, as surmised by the presence of elastic lamellae breaks even 3 weeks after Smad4 deletion ( Figures 4E-4G) . The above data clearly show that modifications of the mechanical properties of the aorta are an early event in aneurysm formation, suggesting that Smad4 inactivation could impinge on the expression of genes relevant for structural stability and functional performance of the vessel. Given that Smad-dependent TGF-b signaling has been identified as a major determinant of differentiation and functional phenotype of SMCs, as well as extracellular matrix (ECM) setup and cell adhesion (Guo and Chen, 2012) , we performed analyses on genes involved in these functions. The expression of several cytoskeletal genes was similar between Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen and those treated with vehicle ( Figure S2F ). Moreover, the phosphorylation of MLC20 and MYPT1, major regulators of SMC contractility and calcium sensitivity, respectively, was also comparable between the two groups ( Figure S2G ). On the other hand, investigation of genes involved in the ECM and cell adhesion revealed some differences. Among numerous genes analyzed, expression of the following six genes varied significantly between control mice and mice with a Smad4 deletion: Eln, Col1a1, Lox (ECM and its metabolism), Itga2 (collagen receptor), and Pxl and Vcl (focal adhesion components) ( Figure S2H ). However, no changes in the transcripts of different proteases were noted ( Figure S2I ).
Smad4 Signaling Negatively Regulates IL-1b Production in SMCs
In addition, analysis of several cytokines and chemokines revealed that the inactivation of Smad4 increased SMC transcripts of IL-1b, IL-6, and CCL2 while reducing those of IL-4, CXCL10, interferon-g (IFN-g), and IFN-b ( Figure 5A ). It is worth noting that the observed changes were most likely related to genes expressed in SMCs of the media, given that the adventitia was carefully removed. On the other hand, this was not surprising because it is well known that IL-1b, despite being produced at high concentrations in stimulated macrophages, was found to be upregulated also in aortic SMCs in human thoracic aneurysms (Johnston et al., 2014) . IL-1b is produced and stored in cells as an inactive precursor, and the release in its active form requires caspase-1 cleavage. In turn, in order to be activated, caspase-1 requires the function of NLRP3, a sensor that is an essential component of the NLRP3 inflammasome, a multiprotein platform that assembles in response to infection and tissue damage to allow the activation of inflammatory caspases (Schroder and Tschopp, 2010 ). Therefore, we tested NLRP3 mRNA amounts and found them to be significantly higher in Smad4
;Myh11-creERT2 mice treated with tamoxifen than in control mice (Smad4 f/f ;Myh11-creERT2 mice treated with vehicle) ( Figure 5A ). When we looked for infiltrating immune cells by flow-cytometric analysis 3 weeks after tamoxifen, we did not find increased CD45 + leukocytes or, more specifically, CD11b + monocytes ( Figures S3A-S3D ), suggesting that immune reaction surged later and further supporting the concept that IL-1b should be activated in SMCs as a danger signal.
To provide additional evidence that deletion of Smad4 in SMCs determined an upregulation of IL-1b in a cell-autonomous way, we analyzed and quantified by confocal microscopy the 5J ). We next looked at the mechanisms responsible for the upregulation of IL-1b in SMCs, determined by the deletion of Smad4. As first, we assessed the possibility that IL-1b could be directly upregulated in SMCs and, to this aim, exploited a typical pro-inflammatory stimulus known to regulate the expression of this cytokine, namely lipopolysaccharide (LPS), the bacterial endotoxin activating Toll-like receptor 4 (TLR4). The in vitro stimulation of SMCs with LPS strongly upregulated the mRNA amounts of the main cytokines that we found upregulated in the vessels deficient in Smad4 signaling and deprived of the adventia layer: IL-1b, IL-6, and CCL2 ( Figures S3E-S3G ). To unravel the specific role of TGF-b signaling in modulating IL-1b production in SMCs in the more complex context of whole aortic tissue, we directly stimulated pressurized vessels with LPS in the presence or absence of TGF-b and assessed IL-1b-producing cells by flow cytometry. As shown in Figures S3H and S3I , the percentage of IL-1b + cells on SMC gating was significantly increased upon LPS stimulation. The concomitant incubation of vessels with TGF-b significantly hampered the LPS-mediated IL-1b production, whereas TGF-b alone had no significant effect ( Figures S3H and S3I ). Similar results were obtained when vessels were incubated with the same protocol and analyzed by confocal microscopy after immunofluorescence staining ( Figures S3J and S3K) .
Together, these data suggest to us that, in principle, TGF-b signaling in SMCs is able to negatively regulate IL-1b when challenged by stimuli such as LPS. To put this observation in the context of the phenotype observed in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen, we attempted to mimic the effect of genetic deletion of Smad4 in the simpler experimental system of pressurized isolated vessels. When aortas from wild-type mice were incubated with the TGF-bRI inhibitor SB525334, IL-1b was markedly increased in SMCs ( Figures S4A-S4C ), thus supporting the concept that TGF-b signaling through Smad4 directly acts as an inhibitor of IL-1b.
IL-1b Activates an Autocrine Pathway in SMCs with a Central Role in the Aortic Pathology of Mice with Inducible Smad4 Deletion in SMCs
Smad4 inactivation is expected to block the transcriptional response stimulated by the canonical TGF-b and bone morphogenetic protein (BMP) pathways. However, in the absence of Smad4, TGF-b receptors remain functionally intact and continue to signal through other paths collectively referred to as nonSmad (non-canonical) signaling (Mu et al., 2012) . These pathways are considered to be of pathogenetic importance for aortic aneurysms with dysregulation of TGF-b signaling, such as those found in Marfan syndrome and LDS. We therefore analyzed the phosphorylation of kinases and regulatory Smads that might take part in non-canonical TGF-b signaling. Silenced Smad4 was accompanied by increased phosphorylation of Smad2/3 and Smad1/5/8 ( Figures S4D and S4E ). However, expression of TGF-b and BMP target genes was not affected ( Figure S4F ). Moreover, except for Smad4 transcript reduction, no variations were detected for other components of the two pathways ( Figures S4G and S4H ). More important, amounts of phosphorylated Erk1/2, p38, and JNK mitogen-activated protein kinase (MAPK) (Figures S4I and S4J) and PKB, also referred to as Akt (data not shown), remained unaltered, thus ruling out the activation of these non-canonical TGF-b pathways. We also tested activation of TGF-b-activated kinase 1 (TAK-1), another MAPK whose activation by TGF-b does not require kinase activity of TGF-b receptors (Mu et al., 2012 ). Although we found no variation in TAK-1 phosphorylation ( Figures S4K and S4L) , to our surprise, we detected significantly increased phosphorylation of a potential downstream signaling component, NF-kB, specifically the RelA subunit, also known as p65 (Figures S4K and S4L) . NF-kB is a transcriptional complex regulated by stimuli such as various types of stress, and it controls a large variety of target genes, several of which are involved in inflammation (Hayden and Ghosh, 2012) . Thus, the increase in P-RelA in SMCs indicates that NF-kB might contribute to the aortic phenotype of Smad4 mutants by inducing modification of the expression of several cytokines and chemokines ( Figure 5A ). In turn, some inflammatory cytokines, including IL-1b, have been reported to affect collagen biosynthesis in various types of SMCs (Amento et al., 1991; Aoki et al., 2009) , thus suggesting that the early mechanical alterations of the vessel and later concomitant recruitment of immune response could be two sides of the same phenomenon-a molecular mechanism activated by Smad4 deletion. The above results suggest that NF-kB and IL-1b might be involved in aneurysm formation due to Smad4 deletion in SMCs. IL-1b can be induced by NF-kB, but it is also an activator of NF-kB (Hiscott et al., 1993; Weber et al., 2010) , hinting at the possibility that positive feedback between the two components might aggravate aneurysm progression. In relation to this issue, we assessed the expression of IL-1 receptor (IL-1R) in the aortas of Smad4 f/f ;Myh11-creERT2 mice treated with vehicle or increased. Student's t test for independent samples (n = 3-8 mice) was applied for Il4 (t (8) = 3.835), Cxcl12 (not significant [ns]), Ccl5 (ns), Ifng (t (8) = 2.302), and Ifnb (t (8) = 2.734). A Mann-Whitney test for independent samples was applied for Il1b, Nlrp3, Il6, Il18, Il10, Ccl2, Cxcl10, and (legend continued on next page) tamoxifen and found a strong colocalization in SMCs ( Figures  S5A and S5B ). Supporting the hypothesis of an autocrine mechanism regulated by positive feedback of IL-1b in SMCs, we found that direct stimulation of SMCs with IL-1b was able to increase the expression of the cytokine itself ( Figure S5C ). In the same setting, IL-1b stimulation was also able to increase the expression of Il6 and the chemokine Ccl2 in SMCs ( Figures S5D and  S5E) , suggesting an apical role of IL-1b signaling in inflammation and activation of the immune response. Therefore, we reasoned that blocking IL-1R might dampen IL-1b signaling and have a beneficial effect on morphological alterations of aneurysms. We tested this hypothesis by inducing Smad4 deletion in SMCs of mice with an Il1r1-null background (Smad4 f/f ;Myh11-creERT2;Il1r1 À/À mice treated with tamoxifen).
Serial ultrasonographic analyses revealed that ablation of Il1r1 protected from pathology progression in the ascending aorta and the abdominal part ( Figures 6A-6D ). Further supporting the protective role of IL-1 inhibition, Kaplan-Meier analysis showed that Il1r1 ablation increased survival of Smad4 f/f ;
Myh11-creERT2;Il1r1
À/À mice treated with tamoxifen ( Figure 6E ).
Overall, these results suggest that increased IL-1 signaling is a central event following Smad4 inactivation. We next tested whether the increase in P-RelA was due to activation of the IL-1 pathway or was independent from it. RelA phosphorylation was analyzed by immunoblotting in the aortas of tamoxifen-treated Smad4 f/f ;Myh11-creERT2 mice with or without the Il1r1-null mutation. P-RelA was significantly more inhibited in tamoxifen-treated Smad4 f/f ;Myh11-creERT2 mice carrying the Il1r1 À/À mutation than in tamoxifen-treated Smad4 f/f ; Myh11-creERT2 mice without the mutation ( Figures S5F and  S5G ), suggesting that NF-kB activation in the media is dependent on IL-1b signaling and not vice versa. In addition, we found that the increased expression of Ccl2 and Nlrp3 in the aortas of Smad4 f/f ; Myh11-creERT2 mice treated with tamoxifen was rescued in the Il1r1 À/À background, whereas the reduced expression of Il4, Ifnb, and Ifng transcripts was normalized ( Figure S5H ), suggesting that these genes were downstream of IL-1b. Deletion of Il1r1 also brought transcripts for Eln, Col1a1, Lox, Itga2, Pxn, and Vcl back to normal amounts ( Figure S5H ). Thus far, these data suggest that IL-1b has a key role not only in the control of cytokines that determine inflammation but also in the expression of genes important for ECM stability and cell adhesion. Further supporting this last observation, we also found that tamoxifen-treated Smad4
Myh11-creERT2 mice on the Il1r1
À/À background were significantly protected from the progressive break of elastic lamellae that occurred in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen ( Figures S5I and S5J) .
To appreciate fully the pathophysiological impact of IL-1b targeting on the aortic disease, we assessed in vivo mechanical properties by echo-tracking the wall motion on ultrasound images. We extracted data relative to arterial stiffness and distensibility. Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen showed a significantly increased index of arterial stiffness, which was already evident 4 weeks after gene inactivation and continued to worsen at the last time point (Figure S5K ). At the same time, Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen displayed less distensibility of the aorta than mice treated with vehicle ( Figure S5L ). The inhibition of IL-1b signaling, obtained in tamoxifen-treated Smad4 f/f ;Myh11-creERT2 mice with the Il1r1 À/À mutation, realized complete protection from the mechanical alterations observed in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen ( Figures S5K and S5L) . These results appear particularly important because they further support a protective effect of IL-1b inhibition on pathology progression in Smad4 f/f ;Myh11-creERT2;Il1r1 À/À mice treated with tamoxifen, despite the moderately increased aortic diameter displayed with time progression (Figures 6A-6D ).
Inhibition of the CCL2-CCR2 Chemokine Axis Blocks Pro-inflammatory Monocyte Infiltration and Ameliorates Aneurysm Progression
The fact that IL-1b was upregulated before infiltration of monocytes and macrophages (Figures 5A and S3A-S3D) suggests that this cytokine plays a role in transferring signals from the aortic walls to the immune system, which is later activated. On the other hand, IL-1b was able to induce the expression of Ccl2 in SMCs ( Figure S5E ), and the peaking of Ccl2 observed 3 weeks after tamoxifen treatment in Smad4 f/f ;Myh11-creERT2 mice was rescued when the deletion of Smad4 was induced in mice with IL-1R deficiency ( Figure S5H ). Given that Ly6C high pro-inflammatory monocytes typically express high amounts of CCR2 (a receptor of CCL2), we hypothesized that the migration of this subset of monocytes, later found infiltrated in the aortic walls of Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen, could be regulated through this pathway. Thus, we generated another murine model to induce the ablation of Smad4 
Myh11-creERT2;Ccr2
À/À mice treated with tamoxifen displayed a slower progression of aortic aneurysm with a significantly reduced diameter both in the ascending and in the abdominal tracts ( Figures 6F-6I ). However, unlike tamoxifen-treated Smad4 f/f ;Myh11-creERT2;Il1r1 À/À mice that manifested early protection from structural damage in the aorta ( Figure S5I Please also see Figure S5 and S6.
started to display the breaks in the elastic lamellae of the vessels 3 weeks after the deletion of Smad4 ( Figure S6A ). Together, these observations suggest that the initial damage in the elastic lamellae of the aorta, despite relying on the activation of IL-1b, was independent from the infiltration of inflammatory monocytes recruited through the downstream activation of CCL2. This conclusion is also in line with the additional evidence showing that early upregulation of IL-1b in SMCs was still observed in mice where deletion of Smad4 was induced in a CCR2-deficient background ( Figures S6B-S6D ). We also analyzed the infiltrating immune cells at 8 weeks, when aortas from Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen were densely enriched with monocytes and macrophages (Figure 3) , and found a significant reduction of Ly6C high pro-inflammatory monocytes in Smad4 
Treated with Tamoxifen
To test the translational potential of our findings, we neutralized IL-1b signaling with the clinically relevant murine version of the FDA-approved clinical drug canakinumab. After tamoxifen administration, used to induce SMC deletion of Smad4, treatment with anti-IL-1b or control immunoglobulin (CTRL IgG) began and was repeated every week. During a time course of 16 weeks, whereas administration of CTRL IgG did not change aneurysm progression, treatment with anti-IL-1b antibody significantly hampered aneurysm formation in both ascending and abdominal tracts of the aorta ( Figures 7A-7D) . The above data not only add support to the mechanistic role of IL-1b in the aortic pathology induced by SMC deletion of Smad4 but also identify treatment with IL-1b inhibitors as potential pharmacological therapy of the disease.
DISCUSSION
Pieces of literature consistently associate disrupted TGF-b signaling with the development of aortic aneurysms. Yet, the molecular mechanisms mediating this association remain to be identified. Our results provide evidence that IL-1b has an important role in triggering aneurysm formation in a model of aortopathy induced by postnatal deletion of Smad4 in SMCs. Indeed, we found that genetic inhibition of the IL-1b pathway significantly hampered progression of aneurysms in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen. More important, blocking IL-1 signaling in Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen reduced the rate of death by aneurysm rupture. To highlight the potential translational use of IL-1 pathway inhibitors, we selectively neutralized IL-1b with the murine version of an antibody that has recently emerged as an effective treatment for secondary prevention of cardiovascular events in the largescale clinical trial CANTOS (Ridker et al., 2017) . The results showed a significant protection from aneurysm progression in both ascending and abdominal aorta, hence opening the door to translational perspectives for limiting aortic Smad4-dependent aneurysm pathology with an already clinically approved drug. This adds to the protective role of IL-1b inhibition previously described in experimentally induced cerebral arterial, abdominal aortic, and thoracic aortic aneurysms (Johnston et al., 2014; Johnston et al., 2013; Moriwaki et al., 2006) .
Our data show that Smad4 is required in SMCs for the maintenance of normal aortic structure and function. In particular, we provide evidence that downregulation of Smad4 stimulates IL-1b expression in SMCs and that this cytokine regulates the function of several other genes, including those encoding other cytokines and chemokines and components of the ECM and its metabolism and focal adhesions.
The finding that that expression of other cytokines is normalized in the Il1r1 À/À background indicates that IL-1b is instrumental for the altered expression of cytokines and chemokines observed in the media early after the induction of Smad4 inactivation. Among upregulated cytokines and chemokines, CCL2 carries out the relevant function of macrophage recruitment, as previously suggested (Zhang et al., 2016) . Relevant to this point, the deletion of Smad4 in SMCs of mice with CCR2 deficiency provoked a milder progression of aortic aneurysm with a significantly reduced diameter both in the ascending and in the abdominal tracts of the aorta, thus unravelling a crucial role of CCL2-induced migration of Ly6C high pro-inflammatory monocytes in the aortic pathology of Smad4 f/f ;Myh11-creERT2 mice treated with tamoxifen. Once recruited into the adventitia, the inflammatory infiltrate of monocytes and macrophages progressively spreads into the media and consequently disrupts this layer's structure and aneurysm enlargement and rupture. In addition, an increased number of LyC6 low F4/80 high monocytes and macrophages have been detected in the aorta. The function of this cell population was not addressed in this study, but their presence could represent a tissue-reparative response to counterbalance the pro-inflammatory burden.
Although the axis dependent on IL-1b and CCL2 is key to aneurysm development, we detected modifications of aortic mechanical properties before any sign of inflammatory cell infiltration into the vessel wall, indicating that an early contribution to dilation could come from changes of the composition or structural organization of the media, possibly derived from the observed downregulation of genes such as Eln, Col1a1, Lox, Itga2, Pxn, and Vcl. Our results suggest that IL-1b is key not only for inflammation but also for regulation of the genes involved in ECM stabilization and cell adhesion.
Abnormal modulation of signaling pathways has been reported in different aneurysm models (Aoki et al., 2007; Gillis et al., 2013) . Among the various analyzed, we obtained evidence of NF-kB activation, specifically a substantial increase in phosphorylation of the RelA subunit. Considering the cross-talk between IL-1b and NF-kB, it was relevant to determine which component could activate the other. By analyzing aortas at a time after Smad4 inactivation when IL-1b expression was increased only in SMCs and not in fibroblasts or hematopoietic cells, we found that the increase in RelA phosphorylation was abolished in mice with the Il1r1-null background. This result excludes that NF-kB activation is the primary effect of Smad4 loss of function. Instead, it appears that Smad4 deletion unlashes IL-1b production and activation by SMCs, and this stimulates NF-kB signaling that in turn sustains IL-1b expression in SMCs.
The relevant finding that IL-1b production was stimulated only in SMCs early after Smad4 inactivation also allows interpretation of the observation that tissue damage, assessed as breaks of elastic lamellae, was substantially reduced by inactivation of the IL-1 receptor. In fact, this implies that damage is secondary to IL-1b activation and not a primary effect of Smad4 deletion driving production of damage effectors such as IL-1b.
Of note, although IL-1b inhibition remarkably ameliorated aneurysm progression, it did not produce complete rescue, suggesting that other factors might be involved in this pathology. We can only hypothesize two tiers of alternative regulation of aneurysm formation: the first depends on a group of molecules that are under the strict control of TGF-b signaling and whose targets were not exhaustively investigated in our study; the second comprises signaling molecules that act in parallel with IL-1b, such as IL-1a and IL-18. The former shares the same receptor with IL-1b but does not require activation, whereas the latter acts through a different receptor but is activated similarly to IL-1b (Garlanda et al., 2013) .
Our study focused on the identification of signaling pathways dysregulated by Smad4 at initial stages of aortic pathology and spotted the important role of IL-1b. However, aneurysm is the outcome of a complex process in which more downstream components of the IL-1b cascade (and other cytokines) might play a similarly relevant role. This could be the case with proteases, whose function has been reported to be either protective or aggravating depending on the aneurysm's location (thoracic or abdominal) and the experimental model used (Alexander et al., 2012; Deguchi et al., 2009; Longo et al., 2002; Martín-Alonso et al., 2015; Shen et al., 2015) . In the present context, the orchestration of the activity of proteases from different cellular sources could determine early breaks of elastic lamellae of the media and, later on, the systematic attack of adventitial inflammatory infiltrates from the outer media inward. In summary, given the SMC-specific recombination in adult animals, we could hypothesize the initial steps of aneurysm development induced by Smad4 inactivation as follows: (1) loss of Smad4 function induces IL-1b expression and activation in SMCs; (2) modulation of CCL2 expression stimulates monocyte recruitment and inflammation in the adventitia; (3) IL-1b also activates NF-kB in SMCs to sustain IL-1b production, establishing an autocrine mechanism further stimulating the recruitment of innate immune response; (4) in parallel, IL-1b modifies the expression of specific SMC genes relevant for ECM composition or metabolism and cell adhesion, thus altering the mechanical properties of the arterial wall and vessel diameter; and (5) all these factors contribute to the development of the aortic aneurysm.
The above pathogenetic scheme highlights the central role of IL-1b in aneurysmal pathology induced by dysregulated TGF-b canonical signaling and indicates this cytokine as an initial target for medical treatment of aneurysms in patients with SMAD4 mutations.
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EXPERIMENTAL MODEL DETAILS
Murine Models All animal handling and experimental procedures were performed according to European Community guidelines (EC Council Directive 2010/63) and the Italian legislation on animal experimentation (Decreto Legislativo D.Lgs 26/2014). All efforts were made to minimize suffering, and the principles of Replacement, Reduction, and Refinement (i.e., the ''three Rs'') were applied to all experiments. Mice were housed in an air-conditioned room (temperature 21 C ± 1 C, relative humidity 60% ± 10%), with lights on from 06:00 to 18:00, and had sawdust as bedding, pellet food, and tap water ad libitum.
Mouse strains used included Smad4 f/f (Bardeesy et al., 2006) , Myh11-creERT2 (Wirth et al., 2008) ,
À/À (Ccr2 tm1/fc , The Jackson Laboratory). All the mice were backcrossed in the C57BL/6 strain (Charles River Laboratories). As the Myh11-creERT2 transgene is Y linked and females do not express the Cre recombinase, only male mice were used. Cre-Lox recombination was induced in 8-to 12-week-old male mice by tamoxifen (T5648, Sigma Aldrich) administration at the dose of 166 mg/kg/day in corn oil by oral gavage for 5 consecutive days. Control groups received corn oil on a similar schedule.
METHODS DETAILS Administration of Neutralizing Anti-IL-1b Monoclonal Antibody
The IL-1b neutralizing antibody was a donation from Novartis (Basel, Switzerland). The antibody selectively binds IL-1b, thus blocking the interaction of the cytokine with its receptors. We treated mice once weekly with a monoclonal mouse anti-mouse IL-1b IgG2a/k antibody (or a mouse monoclonal IgG2a isotype control), after the last day of tamoxifen or vehicle, with subcutaneous injections of 10 mg/kg body/weight (Denes et al., 2012; Sager et al., 2015) .
Blood Pressure Measurement
Blood pressure measurement was performed by tail-cuff plethysmography (BP-2000 Series II, Visitech Systems), as previously described (Carnevale et al., 2014; Zacchigna et al., 2006) , with operators blinded to the experimental group.
Ultrasound Imaging
Ultrasonographic analyses were performed with Vevo2100 (Visualsonics, Fujifilm) equipped by 40 MHz transducer. Mice were anesthetized with isoflurane (5% induction and 1.5%-2.0% maintenance). Cardiac function was obtained by standard echocardiography (Carnevale et al., 2011) . For vascular analysis, the ultrasound transducer was placed on the right side of upper anterior mediastinum for the ascending aorta ( Figure S7A ), and on the mouse abdomen for the abdominal aorta ( Figure S7B ). In order to standardize this projection 3 reference points were used: aortic valve, pulmonary artery, and the brachiocephalic trunk ( Figure S7A) . B-mode images were acquired using Visual Sonics presets and measurements of aortic diameters were obtained using Anatomical M-mode. For the measurement of maximum vessel diameter, sample volume (SV) was positioned on the ascending aorta in correspondence of the center of the pulmonary artery and perpendicular to vessel wall. In our model, abdominal aneurysms developed only in the suprarenal region of the vessels ( Figure S7B ). Thus we acquired B-mode images in correspondence to that point and we measured the maximum vessel diameter through Anatomical M-mode, placing the SV perpendicular to vessel wall. In vivo mechanical properties were assessed through calculations of the following standard parameters (Laurent et al., 2006 and Uç ar et al., 2015, respectively) :
where DA = change in lumen area during systole, A = lumen area during diastole, Dp = pulse pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure, DD = change in lumen diameter during systole, and D = lumen diameter during diastole.
Surgical Procedure and Mounting of Vessels on the Pressure Myograph
For mechanical studies, vessels were excised from mice after cervical dislocation, cleaned of connective and fat tissues, then cannulated and mounted on a pressure myograph (DMT, Danish Myotechnology). The experiments were performed in physiological buffer at 37 C of the following composition: 135 mM NaCl, 5 mM KCl, 1.6 mM CaCl 2 , 1.17 mM MgSO 4 , 0.44 mM KH 2 PO 4 , 2.6 mM NaHCO 3 , 0.34 mM Na 2 HPO 4 , 5.5 mM D-glucose, 0.025 mM EDTA, 10 mM HEPES (pH 7.4). After 30-minute equilibration, vessels were transilluminated under an inverted microscope connected to a computerized system for continuous recording of measures.
Recordings of vessel inner diameters (IDs) and outer diameters (ODs) were taken while increasing the intravascular (transmural) pressure from 0 to 175 mmHg by steps of 25 mmHg (5 min per step). Recordings were also taken while decreasing the pressure following the same steps and timing from 175 to 0 mmHg. Since the thickness of the wall in the large arteries (like the ascending aorta) precluded the localization of the inner wall edge in many transilluminated vessels at pressures lower than 100-125 mmHg, the ID was obtained as an indirect measure, calculated by estimating that vessel wall cross-sectional area (WCSA) remains constant throughout the experimental pressure range. Thus ID can be accurately calculated from OD at any given pressure and from a single measurement of WCSA. Wall/lumen ratio, cross sectional area, circumferential strain, circumferential wall stress, and incremental elastic modulus were calculated according to the following formulas (Trask et al., 2012 For IL-1b immunolocalization by confocal microscopy, vessels were prepared with the same procedure described above and kept pressurized at 125 mmHg for 6 hr in physiological buffer at 37 C. As required by the protocol, vessels were incubated with the following substances: 10 ng/mL LPS from Salmonella Enterica (L5886, Sigma Aldrich), 10 ng/mL recombinant mouse TGF-b (7666-MB, R&D Systems), 10 mM SB525334 (060916, Sigma Aldrich).
Murine Primary SMC Cultures
Arteries were dissected out from wild-type mice and cleaned from surrounding tissues. Arteries were then incubated in 138 U/mL of Collagenase type I (CLS-1, Worthington) in DMEM for 40 min at 37 C. After removing adventitia, the samples were incubated in 0.25% Trypsin-EDTA (Life Technologies) for 6 min at 37 C. The tissue was minced and plated on dishes precoated with 0.1% gelatin in PBS and cultured in DMEM, 20% FBS and penicillin/streptomycin. For the proposed experiments only cells from passage 1 and passage 2 were used.
For mRNA analysis, wild-type SMCs were starved in DMEM, 0.1% FBS, penicillin/streptomycin for 16 hr and then treated with LPS for 6 hr or with 10 ng/mL IL-1b (12340013, Immunotools) for 24 hr, as indicated in figures.
Flow Cytometry
After mice were exsanguinated, aortas were collected and directly analyzed for myeloid staining. For IL-1b analysis, vessels were incubated for 6 hr in the presence of: 10 ng/mL LPS, 10 ng/mL recombinant mouse TGF-b (7666-MB, R&D Systems), 10 mM SB525334 (060916, Sigma Aldrich), as specifically indicated in figures.
Single cell suspensions were obtained as previously described (Carnevale et al., 2014; Carnevale et al., 2016) . In brief, aortas were digested with the following cocktail: Collagensae type XI (C7657, Sigma Aldrich), Collagenase type I (C0130, Sigma Aldrich), Hyaluronidase (H3506, Sigma Aldrich), at 700 rpm for 40 min at 37 C. The digested aortas were them passed through a 70 mm sterile filter (Falcon BD Bioscience) and centrifuged at 1500 rpm for 5 min at 4 C. The pellet was resuspended in a buffer containing 0.5% BSA, 0.1% sodium azide and 2 mM EDTA and number of live cells was assessed using trypan blue and an automated counter (Countess, Life Technologies). Anti-CD16/CD32 (2.4G2, BD Bioscience) was added for 10 min at room temperature (RT) for blocking of nonspecific binding and then primary antibodies were incubated for 20 min at RT. After washing, cells were incubated for 10 min with viability marker 7-AAD (BD Bioscience).
For myeloid cell staining, the following primary antibodies were used: lineage markers (PE-CD49b (clone DX5), PE-CD45R/B220 (clone RA3-6B2), PE-CD90.2 (clone 53-2.1), PE-CD19 (clone 1D3), PE-NK1.1 (clone PK136), PE-Ter119 (clone TER 119) PE-Ly6G (clone 1A8) from BD Bioscience), BUV737-CD11b (clone M1/70), BV421-Ly6C (clone AL-21), Figure S7C .
For IL-1b staining, the following primary antibodies for surface markers were used: BUV395-CD45 (clone 30-F11), BUV737-CD11b (clone M1/70), BV711-CD31 (clone MEC 13.3), BV605-CD29 (clone HM b1-1) from BD Bioscience, BV510-F4/80 (clone BM8) from BioLegend. For intracellular markers, antibodies were added after fixing and permeabilization of samples with the fixation/permeabilization kit BD Cytofix/Cytoperm (BD Bioscience). The primary antibodies for intracellular staining were as follow: FITC-aSMA (clone 1A4, Abcam) and PE-IL-1b/IL-1F2 (clone 166931, R&D Systems) or its isotype PE-IgG2B (clone 141945, R&D Systems). Cells positive for IL-1b were analyzed using the fluorescence minus one (FMO) gating on SMCs (CD45 Figure S7D . Data from the entire sample were acquired on FACSCelesta flow cytometer with FACSDiva software (BD Biosciences) and analyzed using FlowJo software (V10.0.8, Tree Star).
significance was assessed with the appropriate test according to each experimental design, as detailed in figure legends. After assessing distribution of each data setting, we applied Student's t test for independent samples or Mann-Whitney for independent samples, according to the experimental design and as specified in the figure legends. Multiple group analysis was performed with oneway ANOVA or two-way ANOVA followed by Bonferroni's post hoc for data with normal distribution. Analysis for repeated-measures was applied when required by the experimental setting. Multiple group analysis of non-parametric data was performed with KruskalWallis test followed by Dunn's multiple comparison test. p < 0.05 was considered significant. Statistical analyses were performed with SPSS 23.0 (IBM Software) and graphs were made with GraphPad Software PRISM5.
